Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Lancet HIV. 2019 Sep;6(9):e601–e612. doi: 10.1016/S2352-3018(19)30155-9

Figure 2: Median (interquartile range) plasma concentrations (pg/mL) of (A) etonogestrel and (B) ethinyl estradiol from days 0 through 21 of continuous vaginal ring use.

Figure 2:

Participants not yet receiving antiretroviral therapy (ART) are represented in green (Control Group), participants receiving efavirenz–based ART are represented in red (EFV Group), and participants receiving atazanavir/ritonavir–based ART are represented in blue (ATV/r group).